CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Valganciclovir +1 moredrug
Likely dose
Valganciclovir 900mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00264290
NCT00264290Phase 4Completed
CompareCT.gov

Valganciclovir to Reduce T Cell Activation in HIV Infection

University of California, San Francisco·interventional·Posted Dec 12, 2005·Updated Jul 31, 2020

In Brief

A Phase 4 clinical trial evaluating Valganciclovir and Placebo for HIV Infections and Cytomegalovirus Infections. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune responses to antiretroviral therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Cytomegalovirus Infections
CountriesUnited States
CollaboratorsRoche Pharma AG

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2005
Enrollment StartAug 1, 2006
Primary CompletionOct 1, 2008
Study CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 20.6 years ago

Interventions

Valganciclovirdrug

900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.

Placebodrug

Placebo designed to resemble Valganciclovir